keyword
MENU ▼
Read by QxMD icon Read
search

Hepatocellular can

keyword
https://www.readbyqxmd.com/read/28433762/novel-viral-and-host-targets-to-cure-hepatitis-b
#1
REVIEW
Chunkyu Ko, Thomas Michler, Ulrike Protzer
Hepatitis B virus (HBV) infection is a global health threat with 240 million chronic carriers at high risk to develop hepatocellular carcinoma. Current antiviral treatment can efficiently control viral replication and reduce liver inflammation, but is still quite far from achieving a cure. Significant progress has been made in understanding the virus life cycle and virus-host interaction in the past few years. With identification of the HBV receptor, cell-culture infection systems have become available that allow drug screening and establishing a pipeline of potential antivirals targeting either viral or host factors...
April 20, 2017: Current Opinion in Virology
https://www.readbyqxmd.com/read/28432822/focal-liver-lesions-segmentation-and-classification-in-nonenhanced-t2-weighted-mri
#2
Ilias Gatos, Stavros Tsantis, Maria Karamesini, Stavros Spiliopoulos, Dimitris Karnabatidis, John D Hazle, George C Kagadis
PURPOSE: To automatically segment and classify focal liver lesions (FLLs) on nonenhanced T2-weighted magnetic resonance imaging (MRI) scans using a computer-aided diagnosis (CAD) algorithm. METHODS: 71 FLLs (30 benign lesions, 19 hepatocellular carcinomas, and 22 metastases) on T2-weighted MRI scans were delineated by the proposed CAD scheme. The FLL segmentation procedure involved wavelet multiscale analysis to extract accurate edge information and mean intensity values for consecutive edges computed using horizontal and vertical analysis that were fed into the subsequent fuzzy C-means algorithm for final FLL border extraction...
April 22, 2017: Medical Physics
https://www.readbyqxmd.com/read/28432125/sequential-adaptive-changes-in-a-c-myc-driven-model-of-hepatocellular-carcinoma
#3
James M Dolezal, Huabo Wang, Sucheta Kulkarni, Laura Jackson, Jie Lu, Sarangarajan Ranganathan, Eric S Goetzman, Sivakama Bharathi, Kevin Beezhold, Craig A Byersdorfer, Edward V Prochownik
Hepatocellular carcinoma (HCC) is a common cancer that frequently over-expresses the c-Myc (Myc) oncoprotein. Using a mouse model of Myc-induced HCC, we studied the metabolic, biochemical and molecular changes accompanying HCC progression, regression and recurrence. These involved altered rates of pyruvate and fatty acid β-oxidation and the likely re-directing of glutamine into biosynthetic rather than energy-generating pathways. Initial tumors also showed reduced mitochondrial mass and differential contributions of electron transport chain Complexes I and II to respiration...
April 21, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28428881/nano-pulse-stimulation-is-a-physical-modality-that-can-trigger-immunogenic-tumor-cell-death
#4
Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge, Darrin Uecker
BACKGROUND: We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumor growth. We hypothesized that the mechanism for inhibiting secondary tumor growth involves stimulating an adaptive immune response via an immunogenic form of apoptosis, commonly known as immunogenic cell death (ICD). ICD is characterized by the emission of danger-associated molecular patterns (DAMPs) that serve to recruit immune cells to the site of the tumor...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28428725/tumor-biopsy-and-patient-enrollment-in-clinical-trials-for-advanced-hepatocellular-carcinoma
#5
Lorenza Rimassa, Maria Reig, Giovanni Abbadessa, Markus Peck-Radosavljevic, William Harris, Vittorina Zagonel, Davide Pastorelli, Elena Rota Caremoli, Camillo Porta, Nevena Damjanov, Hitendra Patel, Bruno Daniele, Maria Lamar, Brian Schwartz, Terri Goldberg, Armando Santoro, Jordi Bruix
Tumor biopsies may help to reliably distinguish hepatocellular carcinoma (HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients...
April 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28428655/magnetic-resonance-imaging-of-the-cirrhotic-liver-diagnosis-of-hepatocellular-carcinoma-and-evaluation-of-response-to-treatment-part-2
#6
REVIEW
Miguel Ramalho, António P Matos, Mamdoh AlObaidy, Fernanda Velloni, Ersan Altun, Richard C Semelka
In the second part of this review, we will describe the ancillary imaging features of hepatocellular carcinoma (HCC) that can be seen on standard magnetic resonance imaging (MRI) protocol, and on novel and emerging protocols such as diffusion weighted imaging and utilization of hepatocyte-specific/hepatobiliary contrast agent. We will also describe the morphologic sub-types of HCC, and give a simplified non-invasive diagnostic algorithm for HCC, followed by a brief description of the liver imaging reporting and data system (LI-RADS), and MRI assessment of tumor response following locoregional therapy...
March 2017: Radiologia Brasileira
https://www.readbyqxmd.com/read/28427875/easl-2017-clinical-practice-guidelines-on-the-management-of-hepatitis-b-virus-infection
#7
Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L A Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase...
April 18, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28425419/a-rare-bsep-mutation-associated-with-a-mild-form-of-progressive-familial-intrahepatic-cholestasis-type-2
#8
Orith Waisbourd-Zinman, Lea F Surrey, Anna E Schwartz, Pierre A Russo, Jessica Wen
Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2) is a rare cholestatic disorder diagnosed in infancy or childhood that can lead to severe hepatic fibrosis and liver failure. Mutations in the ABCB11 gene result in a deficiency of the bile salt export protein (BSEP) and accumulation of bile inside the hepatocytes. Hepatocellular carcinoma is another condition associated with severe forms of deletion mutations in the ABCB11 gene. Treatment options including ursodeoxycholic acid biliary diversion have mixed outcomes and some patients require liver transplantation...
May 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28425018/hepatocellular-carcinoma-and-liver-transplantation-changing-patterns-and-practices
#9
REVIEW
Nicole E Rich, Neehar D Parikh, Amit G Singal
Benefits of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) are well established. However, there is debate regarding optimal and equitable selection of patients best served by LT, particularly in the face of limited organ availability. Herein, we discuss topics regarding LT selection criteria for patients with HCC. Recent change in UNOS policy currently mandates a 6-month observation period prior to priority listing and institutes a cap of 34 MELD exception points for patients with HCC...
April 19, 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/28424556/nonalcoholic-steatohepatitis-related-hepatocellular-carcinoma-is-there-a-role-for-the-androgen-receptor-pathway
#10
REVIEW
Mahmoud A Ali, Sahin Lacin, Reham Abdel-Wahab, Mark Uemura, Manal Hassan, Asif Rashid, Dan G Duda, Ahmed O Kaseb
The epidemic of insulin resistance, obesity, and metabolic syndrome has led to the emergence of nonalcoholic steatohepatitis (NASH) as the most common cause of liver disease in the US. Patients with NASH are at an increased risk for hepatic disease-related morbidity and death, and chronic inflammation in NASH patients can lead to hepatocellular carcinoma (HCC). The prevalence of HCC is higher in males than in females, and genetic studies have identified androgen and androgen receptors (ARs) as partially responsible for the gender disparity in the development of liver disease and HCC...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28423726/transarterial-embolization-for-hepatocellular-adenomas-a-literature-review
#11
Bao-Hong Yuan, Ru-Hong Li, Bhavesh-K Ahir, Wei-Ping Yuan, Jian-Hong Gu, Tian Yang, Liang Ma
Since the utilization of transarterial embolization (TAE) for hepatocellular carcinoma, TAE is used to treat bleeding hepatocellular adenomas (HCAs) and occasionally, in symptomatic HCAs with large tumors. However, the role of TAE in an elective setting is uncertain. The present review aims to evaluate the benefits and harms of TAE in bleeding and non-bleeding HCAs, especially in an elective setting. A systematic review of studies published from January 2000 to December 2016 in the EMBASE, PubMed and Scopus databases was performed...
March 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423656/effect-of-y6-an-epigallocatechingallate-derivative-on-reversing-doxorubicin-drug-resistance-in-human-hepatocellular-carcinoma-cells
#12
Yan Wen, Rui-Qiang Zhao, Yun-Kai Zhang, Pranav Gupta, Li-Xiang Fu, An-Zhou Tang, Bu-Ming Liu, Zhe-Sheng Chen, Dong-Hua Yang, Gang Liang
Cancer cells can acquire resistance to a wide variety of diverse and unrelated drugs, this phenomenon is termed multidrug resistance (MDR). Multidrug resistance has been an obstacle to the success of cancer chemotherapy. The present study investigated the reversal effect of Y6, a new compound obtained by chemically modifying the structure of epigallocatechin-3-gallate (EGCG) extracted from green tea. Y6 was proven to be effective in inhibiting cell proliferation and reversing drug resistance in doxorubicin (DOX) resistant human hepatocellular carcinoma cells (BEL-7404/DOX)...
March 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423533/spc24-is-critical-for-anaplastic-thyroid-cancer-progression
#13
Huabin Yin, Tong Meng, Lei Zhou, Haiyan Chen, Dianwen Song
In the past 2 decades, the incidence of thyroid cancer has been rapidly increasing worldwide. Anaplastic thyroid cancer (ATC) is the most lethal of all thyroid cancers and one of the most aggressive human carcinomas. SPC24 is an important component of the mitotic checkpoint machinery in the tumorigenesis and high levels of SPC24 have been found in colorectal and hepatocellular carcinomas, but its role in anaplastic thyroid cancer is still unclear. Our results showed that SPC24 was high expressed in human thyroid cancer samples...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423321/hepatocellular-carcinomas-originate-predominantly-from-hepatocytes-and-benign-lesions-from-hepatic-progenitor-cells
#14
Krishna S Tummala, Marta Brandt, Ana Teijeiro, Osvaldo Graña, Robert F Schwabe, Cristian Perna, Nabil Djouder
Hepatocellular carcinoma (HCC) is an aggressive primary liver cancer. However, its origin remains a debated question. Using human data and various hepatocarcinogenesis mouse models, we show that, in early stages, transformed hepatocytes, independent of their proliferation status, activate hepatic progenitor cell (HPC) expansion. Genetic lineage tracing of HPCs and hepatocytes reveals that, in all models, HCC originates from hepatocytes. However, whereas in various models tumors do not emanate from HPCs, tracking of progenitors in a model mimicking human hepatocarcinogenesis indicates that HPCs can generate benign lesions (regenerative nodules and adenomas) and aggressive HCCs...
April 18, 2017: Cell Reports
https://www.readbyqxmd.com/read/28422855/thymalfasin-a-promising-adjuvant-therapy-in-small-hepatocellular-carcinoma-after-liver-resection
#15
Chao He, Wei Peng, Chuan Li, Tian-Fu Wen
There is limited information available concerning the effect of thymalfasin (Tα1) as an adjuvant therapy in hepatocellular carcinoma (HCC) patient who received liver resection. The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection.A total of 206 patients with small HCC who underwent liver resection were analyzed in our retrospective cohort study. Patients were divided into 2 groups: group A (resection + Tα1, n = 44) and group B (resection, n = 162)...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28421483/update-on-embolization-therapies-for-hepatocellular-carcinoma
#16
REVIEW
Sirish Kishore, Tamir Friedman, David C Madoff
PURPOSE OF REVIEW: The purpose of the review is to summarize the latest applications for embolotherapy in the management of patients with HCC according to BCLC stage. RECENT FINDINGS: While traditionally reserved for patients with unresectable HCC and stage B disease, there is an important role for embolization therapies in earlier stage patients as an adjunct to ablation, bridging, or downstaging therapy, as a means to improve safety of resection, and potentially as an arterial ablative option in the case of radioembolization...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28420805/immunotherapeutic-approaches-for-hepatocellular-carcinoma
#17
Vito Longo, Antonio Gnoni, Andrea Casadei Gardini, Salvatore Pisconti, Antonella Licchetta, Mario Scartozzi, Riccardo Memeo, Vincenzo Ostilio Palmieri, Giuseppe Aprile, Daniele Santini, Patrizia Nardulli, Nicola Silvestris, Oronzo Brunetti
Hepatocellular carcinoma (HCC) is a cancer with a high mortality rate due to the fact that the diagnosis usually occurs at anadvanced stage. Even in case of curative surgical treatment, recurrence is common. Sorafenib and regorafenib are the only therapeutic agents that have been demonstrated to be effective in advanced HCC, thus novel curative approaches are urgently needed. Recent studies focus on the role of immune system in HCC. In fact, the unique immune response in the liver favors tolerance, which can represent a real challenge for conventional immunotherapy in these patients...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28420329/contrast-enhanced-us-with-perfluorobutane-sonazoid-used-as-a-surveillance-test-for-hepatocellular-carcinoma-hcc-in-cirrhosis-scan-an-exploratory-cross-sectional-study-for-a-diagnostic-trial
#18
Ji Hoon Park, Mi-Suk Park, So Jung Lee, Woo Kyoung Jeong, Jae Young Lee, Min Jung Park, Kyunghwa Han, Chung Mo Nam, Seong Ho Park, Kyoung Ho Lee
BACKGROUND: Ultrasonography (US) is widely used as a standard surveillance tool for patients who are at a high risk of having hepatocellular carcinoma (HCC); however, conventional B-mode US appears to be insufficient in order to ensure the early detection of HCC. Perfluorobutane allows very stable Kupffer phase imaging for at least 60 min, which is tolerable for examinations of the entire liver. The purpose of our study is to evaluate the added value of contrast-enhanced US using perfluorobutane to that of conventional B-mode US as an HCC surveillance tool for patients with liver cirrhosis...
April 18, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28420236/human-hepatocarcinoma-cell-targeting-by-glypican-3-ligand-peptide-functionalized-silica-nanoparticles-implications-for-ultrasound-molecular-imaging
#19
Marco Di Paola, Alessandra Quarta, Francesco Conversano, Enzo Antonio Sbenaglia, Simona Bettini, Ludovico Valli, Giuseppe Gigli, Sergio Casciaro
Silica nanoparticles (SiNPs) are widely studied nanomaterials for their potential employment in advanced biomedical applications, like selective molecular imaging and targeted drug delivery. SiNPs are generally low cost and high biocompatible, can be easily functionalized with a wide variety of functional ligands and have been demonstrated to be effective in enhancing ultrasound contrast at clinical diagnostic frequencies. Therefore, SiNPs might be used as contrast agents in echographic imaging. In this work, we have developed a SiNPs-based system for the in vitro molecular imaging of hepatocellular carcinoma cells that express high levels of Glypican-3 protein (GPC-3) on their surface...
April 18, 2017: Langmuir: the ACS Journal of Surfaces and Colloids
https://www.readbyqxmd.com/read/28419971/mir-493-5p-suppresses-hepatocellular-carcinoma-cell-proliferation-through-targeting-gp73
#20
Jinli Zhao, Tongsheng Xu, Feng Wang, Weihua Cai, Lin Chen
Aberrant expression of miRNAs has been documented to play critical roles in the development and progression of hepatocellular carcinoma (HCC). However, the expression pattern, functional roles and regulatory mechanism of miR-493-5p in HCC have not been addressed. Herein, we found that miR-493-5p was significantly downregulated in HCC tissues and was tightly associated with tumor size, tumor differentiation grade and TNM stage of HCC patients. Overexpression of miR-493-5p inhibited HCC cell proliferation, arrested cell cycle in G0/G1 phase and induced cell apoptosis...
April 15, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
keyword
keyword
55330
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"